Get started

UNH

UNH: Why I Believe This Is a Dead Cat Bounce(Late posting)We’ve seen a quite the abounce in the market as of lately, but I believe it’s not a real recovery. To me, this looks like a classic dead cat bounce; a quick move up that happens during a downtrend before prices drop again. I’ll explain why I think this is the case, kind of a simple one. First of all, the grand picture in the economy still looks fairly negative, especially respecting the TRUMP TARIFF new. Inflation hasn’t fully gone away, interest rates are still high, and consumer confidence is weak. There’s no major change in the news or the fundamentals that would support a strong comeback. It feels like people are just hoping things will improve, but the facts don’t really support that yet. Second, the volume on this bounce has been low. In trading, volume tells you how strong a move is. If the price goes up but not many people are trading, it usually means there’s not much real buying happening. This bounce seems to be driven more by short sellers covering their positions, not by confident investors jumping in. Third, we’re hitting key resistance levels—areas where the price dropped before—and we’re starting to see signs of rejection again. These levels are often hard to break through unless the market has strong momentum, and right now it doesn’t look like that’s the case. Fourth, if you look at indicators like the RSI and MACD, they show that the price is already overbought. That means the recent move up may have gone too far, too fast. These kinds of readings usually lead to a pullback, especially when the bigger trend is still down. Finally, the overall structure of the chart hasn’t changed. We’re still making lower highs and lower lows, which is what a downtrend looks like. Just because we’ve had a few green candles doesn’t mean the trend has reversed. Until we see the market start building a base and making new highs with strong support, I don’t think this bounce will last. I n my opinion, this is one of those moments where people might get too excited too quickly. A lot of traders jump in thinking the bottom is in, only to get caught when the price turns back down. That’s why I’m staying cautious and watching for signs that the bounce is failing. I could be wrong, but right now, this feels more like a trap than a turning point.
NYSE:UNHShort
by ThePlotThickens
3
$UNH still looks very uglyI'm still bearish on NYSE:UNH until 335-340 area gets taken out. The chart is so ugly. We've seen many "too big to fail" companies die out eventually. Will NYSE:UNH survive all this bad publicity? Insider action, options flow suggest this isn't going "parabolic" anytime soon lol sorry bulls The technicals just don't align YET to the upside. This is still so far from major moving averages on the higher time frames... the volume dried out after those huge moves and consumers hate them right now lol.. this is feeling like NYSE:GME apes versus wall street bullies. Except its NYSE:UNH versus the insured consumers finance.yahoo.com 20EMA on the daily = 342 still not even close Also FYI - NYSE:UNH is not the type of stock that goes parabolic, nothing sexy on the options flow either Below 290, I've got 275, 260, and 210 gap down. Good luck bulls and bears
NYSE:UNHShort
by chrisgxtct6663
UnitedHealth (UNH) Share Price ReboundsUnitedHealth (UNH) Share Price Rebounds A month ago, in our analysis of the UNH chart, we: → highlighted that UnitedHealth shares had lost nearly 23% in value; → drew a descending channel and suggested that bearish pressure could continue, threatening the support level around $450, which had held since early 2022. Since then, UNH’s stock price decisively broke below that level (as marked by the arrow), falling to around $250 — its lowest point since spring 2020 — before staging a sharp rebound. This steep price movement was driven by a series of fundamental developments, including: → the resignation of the CEO and news of a Department of Justice investigation into potential Medicare fraud; → UnitedHealth withdrawing its earnings guidance for the coming year; → political debates over the Medicaid programme as part of the 2025 budget negotiations; → President Trump’s directive to cut prescription drug prices. Recent news that the new CEO and several top executives have bought tens of millions of dollars’ worth of UNH shares appears to have renewed investor confidence — the share price rose above the $300 mark yesterday. Technical Analysis of UNH Share Chart These latest developments justify an update to the descending channel configuration. Of particular note is the gradual decline with limited volatility — a sign that the price is moving along the channel's median line (highlighted on the chart). In this setup: → the bounce from the $250 level points to the lower boundary of the channel; → traders may consider a scenario where the current recovery pushes UnitedHealth stock towards the median, after which supply pressure may return and offset the recent dominance of demand. It’s also possible that the key psychological level of $300 could now act as support. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:UNH
by FXOpen
$UNH: With stock down more than 60%, is it in buy zone? NYSE:UNH with one after bad news lost 60% of its market cap from its ATH of 600$. NYSE:UNH the largest insurer in US has been in news for all the wrong reasons. The stock after losing 60% of the value has a dividend yield of 3.1% which is 2.5 times of the S&P Yield. The historical dividend growth of NYSE:UNH has been more than 8%. This makes NYSE:UNH a compelling story stock during the recent downturn. With recent insider buys of the NYSE:UNH stock most of the fundamental indicators indicate a positive outlook. But what are the technical indicators telling us? Today we are looking at the historical chart of the stock. The last time the stock was down more than 60% was during the 2007-2008 Financial recession. In 2008 it did lose more than 64%. If we investigate the long term RSI then we see it below 25 which we also saw last during the Financial recession. Verdict : Buy 1/3 @ 250, Buy 1/3 @ 275, Buy 1/3 now.
NYSE:UNHLong
by RabishankarBiswal
1
UNH can retrace the fib and come back to the lowSee trading is all about risk and probability. There is news flowing left and right about insiders buying UNH for the dip, a director bought about $1m single handedly. But remember, DOJ is serious about the Medicare Fraud Probe. I believe since there is a huge, huge downfall from April 16, 2025... there will definitely be a retracement, but not till .5 or .618, imo. So after retracement to 381 range, it may again fall down to 250 low ( as rapid downfall, suggests retracement to only 0.38 range, from my personal experience). Huge Volume spike is also seen stating a lot of people are being involved in this stock. Some may try to get rid off it as soon as possible, some might speculate the comeback of UNH to 594 normal range.
NYSE:UNHShort
by FinExcel
UnitedHealth Group | UNH | Long at $323.00UnitedHealth Group NYSE:UNH currently has a P/E near 15x, steady rising revenue (2024 = $400+ billion), EPS of 6.24x, dividend of 2.2%, and earnings are forecast to grow by 10.8% per year. The stock, however, has plummeted recently due to negative news, rising healthcare costs, CEO changes, and suspension of 2025 outlook. Every company has bumps, but I view solid companies like NYSE:UNH as pure opportunities for long-term investment - especially with America's aging population. From a technical analysis perspective, the stock price has entered my "crash" simple moving average zone (which currently extends down near $307.00). Personally, this is the zone I am starting a position due to the odds of a future bounce from here. However, I am very aware that there is an open price gap near $265.00 that may get filled this year or early next. I could see a bounce in my crash zone to bring in the bulls and then a drop to that level to heighten the fear. That is another area I plan to grab more shares and build a strong position. But, in case it doesn't extend that low, I have started a position at $223.00, with future investments near $307.00 and below. I doubt this will be a quick turnaround stock - patience is where money is made. Targets (into 2028): $375.00 $475.00 $580.00
NYSE:UNHLong
by WorthlessViews
UNH: Knife or Generational Opportunity?News today that NYSE:UNH suspended 2025 guidance and CEO stepped down led to a massive route... right down to the 50% Retracement from the 2008 bottom to the former All Time High. This is potentially a big opportunity for a long term position at this level: 322. I would have preferred the level to be matched by a Volume Profile level but the nearest one below is at 244. I can still see a good risk adjusted trade back to the median of the down move initially and onward to a full recovery. I took a moderate position in tax advantaged accounts for the long term hold and will keep an eye on this level for a more tactical setup (a spike or further price action to confirm the hold).
NYSE:UNHLong
by norok
11
$UNH Rinse & Repeat Round #2- Fundamentally it's undervalued for the quality blue chip company. My detailed analysis is on the older post I made earlier this year. I have attached that as a reference. - In my previous swing, I bought NYSE:UNH on a sell off @ 441 and sold @600 before earning as a de-risking strategy. I'm glad that it did work out. - I'm happy that NYSE:UNH is again trading at a discount and with compressed Earning multiple. This time I am buying it even lower than where I bought last time i.e 441 and I was happy with that price average. - Whereas I do believe that NYSE:UNH EPS is lowered but it is lowered slightly which doesn't warrant a big sell off like this. - I wanted to wait further before entering but I can't stop myself from buying this name NYSE:UNH at a price where I believe it's very undervalued. - Therefore, I have re-entered the NYSE:UNH and added it to my portfolio . I will consider adding further if selling pressure continues because I don't want to time the bottom. - But undecisive market and lumpy market, going with a defensive name like this is a no brainer.
NYSE:UNHLong
by bigbull037
2
UnitedHealth (UNH) Share Price PlummetsUnitedHealth (UNH) Share Price Plummets UnitedHealth shares crashed by nearly 23% yesterday after the healthcare giant reported weaker-than-expected Q1 2025 results: → Earnings per share: actual = $7.20, expected = $7.29 → Revenue: actual = $109.5bn, expected = $111.5bn Technical Analysis of UNH Share Chart As far back as a year ago, we highlighted key support around the $450 level. Yesterday’s negative news caused this support to once again demonstrate its strength by holding back further decline — but will it hold? Taking the price action marked on the chart as a base, we can establish the structure of a descending channel (shown in red), with the price gapping sharply lower into the bottom half of this channel — and yesterday’s candle high (marked with an arrow) suggests that the median line has turned into resistance. Yesterday’s candle closed near its lows, so it is reasonable to assume that bearish pressure may persist (with the aim of testing the lower boundary) — in which case, the $450 support zone, in place since early 2022, could be at risk. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:UNH
by FXOpen
1
$UNH buy the fear or sell into narrative?- NYSE:UNH has gotten into trouble with bad headlines after bad headlines. - Recent DOJ probe led to 12% shaving in the stock price. - Could it be a buying opportunity or just a falling knife? - Are you afraid that NYSE:UNH could become NYSE:HUM 2.0? Let's talk about fundamentals! Year | 2024 | 2025 | 2026 | 2027 | 2028 GAAP EPS | 15.76. | 28.22 | 32.11 | 36.80 | 41.11 EPS growth% | -33.47% | 79.08% | 13.77% | 14.61% | 11.71% It appears that 2024/ Early 2025 was the year when EPS growth bottomed and would go from negative to positive back again. EPS growth is healthy double digit in mid teens. A fair forward p/e multiple for mid teen EPS growth should at least be 15 ( conservatively ) Year | 2024 | 2025 | 2026 | 2027 | 2028 Fair Stock Price (w/ forward p/e = 15 ) | $236 | $423 | $481 | $552 | $616 However, NYSE:UNH is a blue chip company and has a moat. Therefore, Investors will be willing to pay forward p/e of 20 once negative news subside. Year | 2024 | 2025 | 2026 | 2027 | 2028 Fair Stock Price (w/ forward p/e = 20 ) | $315 | $564 | $642 | $736 | $822.2 Final Take: I'm a buyer of NYSE:UNH < 450 will add more if it dips below 400 for the long term. Good quality companies don't usually buyers to get their skin into the game. Therefore, it's better to buy the fear than selling into narrative.
NYSE:UNHLong
by bigbull037
5
$UNH: UnitedHealth Group – Healthcare Hero or Reform Risk?(1/9) Good evening, everyone! 🌙 NYSE:UNH : UnitedHealth Group – Healthcare Hero or Reform Risk? With UNH at $505.69, post-7% drop, is this healthcare giant a safe bet or a reform casualty? Let’s diagnose! 🔍 (2/9) – PRICE PERFORMANCE 📊 • Current Price: $ 505.69 as of Mar 18, 2025 💰 • Recent Move: Stable after 7% drop, per user data 📏 • Sector Trend: Healthcare sector mixed with reforms and economic factors 🌟 It’s a steady pulse—let’s see if it’s time to buy or hold! ⚙️ (3/9) – MARKET POSITION 📈 • Market Cap: Approx $465B (920M shares) 🏆 • Operations: Health insurance and services across the U.S. ⏰ • Trend: Leading player with strong fundamentals, per data 🎯 Firm in healthcare, but reforms keep it on its toes! 🏥 (4/9) – KEY DEVELOPMENTS 🔑 • Mixed News: Healthcare reforms debated, earnings reports mixed, per user data 🌍 • Q4 2024 Earnings: Assume beat or miss based on context, per data 📋 • Market Reaction: Stabilized after drop, showing resilience 💡 Navigating through choppy waters! 🛳️ (5/9) – RISKS IN FOCUS ⚡ • Healthcare Reforms: Regulatory changes could impact business 🔍 • Competition: Other insurers and providers in the market 📉 • Economic Slowdown: Reduced consumer spending on healthcare ❄️ It’s a risky prescription—watch the side effects! 🛑 (6/9) – SWOT: STRENGTHS 💪 • Market Leader: Dominant in U.S. healthcare 🥇 • Diversified Portfolio: Insurance and services balance risk 📊 • Financial Strength: Strong earnings and cash flow, per data 🔧 Got the muscle to handle challenges! 🏦 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES ⚖️ • Weaknesses: Regulatory scrutiny, high debt (if any) 📉 • Opportunities: Aging population, tech advancements in healthcare, per data 📈 Can it capitalize on growth or stumble on weaknesses? 🤔 (8/9) – POLL TIME! 📢 UNH at $505.69—your take? 🗳️ • Bullish: $600+ soon, reforms are manageable 🐂 • Neutral: Steady, risks balance out ⚖️ • Bearish: $450 looms, reforms hit hard 🐻 Chime in below! 👇 (9/9) – FINAL TAKEAWAY 🎯 UNH’s $505.69 price reflects stability after a drop, with mixed news and reforms in play 📈. DCA-on-dips could be a strategy to manage volatility. Gem or bust?
NYSE:UNHLong
by DCAChampion
The Ugly Truth of Technical Analysis...Even though this may be an extremely unpopular opinion on this topic, realizing this simple truth may be what makes or breaks a profitable trader. The truth is this... Drawing lines on a chart does not predict any price movement, and there are more factors in play than simply price action It doesn't matter what the gurus on the internet say about some "secret strategy" or a "secret indicator", anyone with common sense should automatically ignore content like that. Firms like NYSE:JPM , NYSE:GS , NYSE:MS , etc. , spend billions upon billions of dollars just to figure out how to trade the market with efficiency, but some random 19 year old on the internet figured out how to beat these mega-firms with a free indicator. Yeah right. However, I'm not saying that technical analysis doesn't work or that it shouldn't be used; I'm simply saying to reconsider your strategy and use common sense before donating your money to Wall Street banks. Below is an example of technical analysis working perfectly on NYSE:UNH for the 1D timeframe looking back into April of last year. This would have been a textbook channel breakout trade, in which the trader takes a short when the bottom trendline is broken (or the candle closes below the trendline). It would have resulted in a maximum of 17% gain on naked short shares if the bottom penny is the exit price (which is virtually impossible). So there you have it... technical analysis works perfectly and I have proven myself wrong.... right? No. . Now let me show you what really happened. Here is the same exact chart, but this time with a piece of key information shown. As it turns out, there was nothing technical in play at all in this price action, but rather a "fundamental" or a "tangible" aspect was the price driver. An example like this should also show you that not providing sufficient information and taking charts out of context can be done by literally anyone. If you think you can predict the future with some geometric shapes, bars, and non financial, fundamental, or tangible analysis, better than the top Wall Street firms, I say good luck to you. WITH THAT BEING SAID, this does not mean that trendlines, price areas, value gaps, and other technical indicators are completely invalid, but it does mean that there is more to the story than what is on the chart. Always review news, sentiment, financials, analyst ratings, and other key oscillators to gauge every trade. Disclaimer: The indicators used on the chart are only for illustrative purposes of a cluttered chart. I am neither saying that they are accurate nor inaccurate.
NYSE:UNH
by addatheriver0808
UNITEDHEALTH GROUP | THE BEAR'S CLAIM: $UNH PAYS THE PRICE Dec17UNITEDHEALTH GROUP | THE BEAR'S CLAIM: NYSE:UNH PAYS THE PRICE Dec17 UnitedHealth Group, NYSE:UNH , UNH NYSE:UNH Trends: NYSE:UNH Weekly Trend: Bearish NYSE:UNH Daily Trend: Bearish NYSE:UNH 4H Trend: Bearish NYSE:UNH 1H Trend: Bearish NYSE:UNH Price Target Areas: NYSE:UNH BUY/LONG ZONE (GREEN): $488.75 - $514.75 NYSE:UNH DO NOT TRADE/DNT ZONE (WHITE): $480.00 - $488.75 NYSE:UNH SELL/SHORT ZONE (RED): $455.00 - $480.00 All indicators are pointing to bearish for $UNH. Looking at the monthly timeframe we can see there is a range that was respected between the levels of 480 up to 555. After price finally broke the level of 555 a new range began. 560 up to 615/620 area. Given the recent news and events; the stock has since seen a deep bearish trend. Momentum has taken price all the way back down to the previous range low of 480. Price currently rests on 480. Bears should seek continuation and target levels of 455/460, or even down to 415. Bulls should look for a reversal marked by breaks over 488.75 on the lower timeframes, or the 549 area for a higher frame reversal. This is what I would personally look at before entering trades, everything is subject to change on a daily basis and as I analyze different timeframes and ideas. ENTERTAINMENT PURPOSES ONLY, NOT FINANCIAL ADVICE! trendanalysis, trendtrading, priceaction, priceactiontrading, technicalindicators, supportandresistance, rangebreakout, rangebreakdown, rangetrading, chartpatterntrading, chartpatterns, unh, unitedhealth, unitedhealthgroup, NYSE:UNH , insurance, insuranceclaims, unhinsurance, unhclaims, unhdeductible, unhstock, unhprice, unhtarget, unhsetup, unhtrade, unhzone, medicare, unhanalysis, unitedhealthanalysis, unhtradeidea, unhidea, unhrecentevents,
NYSE:UNHShort
by TonyAiello
UNH | UnitedHealth Group (UNH) | BearishNYSE:UNH Technical Analysis of UnitedHealth Group (UNH) Key Observations: Current Price Action: Price: $498.50 Recent Drop: -21.98 (-4.22%) Support and Resistance Levels: Immediate Support: $475.87 (Target Price 1) Further Supports: $436.72 (Target Price 2) Resistance: The price recently broke below previous support around $525-$530, confirming bearish momentum. Trendlines: The price has clearly broken below a key upward trendline. The breakdown signals a shift from a bullish to a bearish trend, with lower highs (LH) and lower lows (LL) forming. Relative Strength Index (RSI): Current RSI: Below 30 (Oversold Zone). The RSI indicates heavy selling pressure, suggesting the stock may be oversold, but bearish momentum remains intact. Target Prices: Target Price 1: $475.87 This level acts as immediate support where price could pause or consolidate. Target Price 2: $436.72 If the price breaches the $475.87 level, the next key support lies at $436.72. Summary: UnitedHealth Group (UNH) is showing clear bearish signs, having broken below critical support and its upward trendline. The RSI indicates an oversold condition, but momentum remains downward. Key levels to monitor are $475.87 (Target 1) and $436.72 (Target 2). Any recovery will need to overcome resistance at $525-$530 for a trend reversal.
NYSE:UNHShort
by shkspr
UNH Selloff Unreasonable - Still 15% ROI Short-TermSince my first NYSE:UNH idea a couple of days ago the price of this stock dropped significantly. If you've been part of the first idea you should've been able to lock in around 1.x% of return when using a tight stop-loss. Otherwise you've been stopped out with break-even. Nevertheless, the sell-off was not helpful and is completely exaggerating the situation at UNH since the company is not really effected by the current PBM debate. "Deutsche Bank sees a potential divestiture as not having a significant impact on earnings, estimating the risk at likely less than $200M of the company’s roughly $30B+ operating earnings. Deutsche Bank noted, however, that CVS (CVS), Cigna (CI) and UnitedHealth (NYSE:UNH) 'could face additional risk from losing the ability to vertically integrate the PBM, fulfillment and manufacturing functions of biosimilars through organizations like Cordavis and Quallent.' Despite concerns about the potential breakup of their pharmacy businesses, Deutsche Bank maintained it's buy rating on UnitedHealth (UNH)." From a technical standpoint we can see a confluence of support: Weekly SMA200 Strong Trendline from March 2020 Horizontal Support at $480 UNH managed to bounce from the trendline intraday today. This could mean we're going to see a turnaround from here. If we break below the trendline on the daily chart this trade will be invalidated. Otherwise our target sits at $550.
NYSE:UNHLong
by LGNDRY-Capital
1
Buy Recommendation Note for UnitedHealth Group (UNH)Recommendation: Buy Buy Zone: $551.50 - $557.00 Target: $600.00 (Short-Term), $650.00 (Medium-Term) Rationale Strong Fundamentals: UnitedHealth Group has consistently delivered robust revenue growth driven by its diversified healthcare services and insurance offerings. Industry Leadership: As a leader in the healthcare sector, UNH benefits from its scale, market share, and innovative healthcare solutions, ensuring long-term stability. Positive Outlook: Recent developments and earnings reports indicate strong growth potential, supported by increasing demand for managed healthcare services. Valuation: Current levels provide a favorable risk-to-reward ratio for entry, with the stock trading near a key support zone. Technical Analysis The stock has shown strong support in the $551.50 - $557 range, making it an attractive buying opportunity. A breakout above $560 could signal a bullish continuation toward the target zones. Technical Analysis The stock has shown strong support in the $551.50 - $557 range, making it an attractive buying opportunity. A breakout above $560 could signal a bullish continuation toward the target zones. Disclaimer: This note is for study and informational purposes only. The recommendations and price levels mentioned are based on market observations and are not a guarantee of performance. Please consult with a licensed financial advisor and carefully consider your risk tolerance before making any investment decisions. Past performance is not indicative of future results. Investing in stocks carries inherent risks, including the potential loss of capital.
NYSE:UNHLong
by KSLBroking
4
UNH Bounce - Don't Miss Out On This 15% OpportunityNYSE:UNH dropped after the tragic death of UnitedHealthcare CEO (not UNH Group CEO) as well as public backlash. Nevertheless, as always in such situation, this has nothing to do with the stock itself. As price action traders we do not trade political or news events since those drops have an unimportant impact mid- to long-term. UNH now sits on the support zone at around $550 which was previous resistance. We also filled the daily gap at around $568 completely. We touched the 0.236 Fib from the $273 bottom (from 2020) and the RSI is nearly oversold on the daily. This gives us a got chance for a bounce from this zone up to $600 - $620. Support Levels: $550 $528 Target/Resistance Levels: $600 $622-628
NYSE:UNHLong
by LGNDRY-Capital
1
$UNH Bad News Longs.NYSE:UNH Recent news should (I believe will) put an end to the madness imaginary run from the corrupt world of health insurance. News circulating NYSE:UNH was a top denier of benefits and claims, only will get worse. A CEO involved in a hit sh**ting? They won't find the "guy" and I assume they will make an arrest but not the actual one who did it. Mmn, conspiracy, yes. But, similar pattern evolving on the chart as well, almost like it all makes sense. Might be a good time to short the health/insurance sector.. maybe.. BlueCross BlueShield just cut back on paying for patients anesthesia in NY, CT, and MO. They are against the people.. biggest ponzi-scheme ever. $555 target, break $500 I see $530. A lot of bearish flow poured in today as well. Months out puts. Not financial advice. wall street .. loser
NYSE:UNHShort
by wallstreetloser001
UnitedHealth Group ($UNH) Faces Surge in Medical CostsUnitedHealth Group Inc. (NYSE: NYSE:UNH ), one of the largest health insurers in the United States, reported a 3% drop in share price following its Q3 2024 earnings report. The company's results highlighted an uptick in medical costs as it grapples with challenges in its insurance business, including lower government payments and persistently high healthcare demand. Let’s break down the key aspects driving the stock's recent performance. Elevated Costs and Earnings Beat UnitedHealth's Q3 2024 results showed a significant rise in its medical loss ratio (MLR)—the percentage of premiums used to cover medical costs. The MLR rose to 85.2%, exceeding both last year’s figure (82.3%) and analysts’ expectations of 84.2%. This surge in costs is attributed to an increase in healthcare services under Medicare plans, particularly for individuals aged 65 and older, as postponed procedures from the COVID-19 pandemic catch up. Additionally, turnover in Medicaid has left insurers with a sicker patient base, further elevating costs. Despite these challenges, UnitedHealth delivered an adjusted profit of $7.15 per share, beating Wall Street estimates by 15 cents. The company's revenues hit $100.8 billion, surpassing the $99.28 billion expected by analysts, thanks to strong growth in its healthcare services businesses under Optum and insurance offerings under UnitedHealthcare. Key highlights: - Optum Health revenue grew by $2.1 billion, driven by the expansion of value-based care and in-home patient services. - Optum Rx, the company’s pharmacy services division, saw revenue growth of $5.4 billion, fueled by new clients and expanded pharmacy offerings. - Medicare and Medicaid pressures persisted, with the company facing government funding reductions and a sicker Medicaid population due to eligibility redeterminations. While the overall financial performance was positive, the rise in medical costs and increased demand for healthcare services, particularly from Medicare and Medicaid plans, weighed on investor sentiment, contributing to the drop in stock price. Technical Outlook: Bearish Signs Emerge On the technical front, NYSE:UNH stock has entered a bearish trend following the earnings report, and it is currently down 3.54% in Tuesday’s pre-market trading. On Monday, the stock saw a 1.60% gain but quickly reversed as the negative aspects of the earnings report began to dominate market sentiment. The stock has broken below its symmetrical triangle pattern, confirming a bearish continuation pattern. The Relative Strength Index (RSI) was 66 on Monday, indicating the stock was approaching overbought territory. However, the sharp decline in pre-market trading has relieved some of this pressure. If the bearish momentum continues, the RSI could dip below 50, signaling further downside potential. Immediate support lies at $530, the base of the triangle pattern, where the stock may find some consolidation. The stock is currently hovering around its 50-day. A break below these levels could reinforce the bearish sentiment and signal further downside to come. What Can Investors Expect? From a fundamental perspective, UnitedHealth's revenue growth and earnings beat show that the company remains a leader in the healthcare sector, with its Optum businesses continuing to drive profitability. However, the elevated medical costs, particularly related to Medicare and Medicaid, could be a persistent headwind. Regulatory changes or adjustments in Medicaid enrollment could also add to volatility in the coming quarters. On the technical side, the break below the triangle pattern is a bearish signal, and further downside toward the $530 support level seems likely if sentiment does not improve. Investors should watch for signs of consolidation at these levels or a potential breakdown, which could push the stock even lower. Conclusion UnitedHealth Group (NYSE: NYSE:UNH ) remains a strong company with a diverse portfolio spanning insurance and healthcare services. However, its near-term outlook is clouded by rising medical costs, Medicare funding challenges, and Medicaid enrollment fluctuations. Technically, the stock is in a bearish phase, but key support levels could provide opportunities for long-term investors if the stock consolidates or rebounds.
NYSE:UNHShort
by DEXWireNews